CN1235638C - 活性蛋白c制剂 - Google Patents

活性蛋白c制剂 Download PDF

Info

Publication number
CN1235638C
CN1235638C CNB988045672A CN98804567A CN1235638C CN 1235638 C CN1235638 C CN 1235638C CN B988045672 A CNB988045672 A CN B988045672A CN 98804567 A CN98804567 A CN 98804567A CN 1235638 C CN1235638 C CN 1235638C
Authority
CN
China
Prior art keywords
lyophilized formulations
sucrose
filler
sodium chloride
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988045672A
Other languages
English (en)
Chinese (zh)
Other versions
CN1254284A (zh
Inventor
A·D·卡尔森
T·A·舍利加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1254284A publication Critical patent/CN1254284A/zh
Application granted granted Critical
Publication of CN1235638C publication Critical patent/CN1235638C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB988045672A 1997-04-28 1998-04-24 活性蛋白c制剂 Expired - Fee Related CN1235638C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
US60/045255 1997-04-28
US60/045,255 1997-04-28

Publications (2)

Publication Number Publication Date
CN1254284A CN1254284A (zh) 2000-05-24
CN1235638C true CN1235638C (zh) 2006-01-11

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988063824A Expired - Fee Related CN1227025C (zh) 1997-04-28 1998-04-24 改进的加工活化c蛋白的方法
CNB988045672A Expired - Fee Related CN1235638C (zh) 1997-04-28 1998-04-24 活性蛋白c制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB988063824A Expired - Fee Related CN1227025C (zh) 1997-04-28 1998-04-24 改进的加工活化c蛋白的方法

Country Status (34)

Country Link
US (4) US6162629A (enExample)
EP (2) EP0875252B1 (enExample)
JP (2) JP4383546B2 (enExample)
KR (2) KR100564189B1 (enExample)
CN (2) CN1227025C (enExample)
AR (2) AR012010A1 (enExample)
AT (1) ATE285788T1 (enExample)
AU (2) AU740753C (enExample)
BR (2) BR9809304B1 (enExample)
CA (2) CA2288143C (enExample)
CO (2) CO4940438A1 (enExample)
CZ (1) CZ298429B6 (enExample)
DE (1) DE69828330T2 (enExample)
DK (1) DK0875252T3 (enExample)
EA (2) EA004881B1 (enExample)
EG (1) EG23685A (enExample)
ES (1) ES2234072T3 (enExample)
HU (2) HU224826B1 (enExample)
ID (2) ID22933A (enExample)
IL (2) IL132325A (enExample)
IN (2) IN183798B (enExample)
MY (2) MY118591A (enExample)
NO (2) NO995134L (enExample)
NZ (2) NZ337828A (enExample)
PE (2) PE84799A1 (enExample)
PL (2) PL195642B1 (enExample)
PT (1) PT875252E (enExample)
SI (1) SI0875252T1 (enExample)
SV (2) SV1998000050A (enExample)
TR (2) TR199902529T2 (enExample)
TW (2) TWI242443B (enExample)
UA (2) UA55448C2 (enExample)
WO (2) WO1998048822A1 (enExample)
ZA (2) ZA983497B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
DE69930419T2 (de) * 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
EP1131091B1 (en) * 1998-11-20 2003-04-02 Eli Lilly And Company Treatment of viral hemorrhagic fever with protein c
DE69905489T2 (de) * 1998-11-23 2003-09-11 Eli Lilly And Co., Indianapolis Protein c zur behandlung von sichelzellanämie und thalassämie
JP2002531519A (ja) * 1998-12-10 2002-09-24 イーライ・リリー・アンド・カンパニー 血栓性血小板減少性紫斑病および溶血性尿毒症性症候群の処置法
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EA200400549A1 (ru) 2001-10-15 2005-02-24 Чирон Корпорейшн Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
CA2475738A1 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
KR20050083841A (ko) * 2002-10-29 2005-08-26 알자 코포레이션 안정화된 고체상태 폴리펩타이드 입자
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
US9175283B2 (en) * 2006-05-31 2015-11-03 Genzyme Corporation Use polysaccharides for promotion of enzymatic activity
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
EP2527364A1 (en) * 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2834635A4 (en) 2012-04-03 2015-09-02 Smiths Medical Asd Inc COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3137102B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
NZ788906A (en) * 2016-06-01 2025-07-25 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
PL195642B1 (pl) 1997-04-28 2007-10-31 Lilly Co Eli Sposób przetwarzania wodnego roztworu aktywowanego białka C
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
ZA983496B (en) 1999-10-25
EP0875252B1 (en) 2004-12-29
JP4383547B2 (ja) 2009-12-16
DK0875252T3 (da) 2005-04-25
JP2001524111A (ja) 2001-11-27
DE69828330T2 (de) 2005-10-13
KR20010020325A (ko) 2001-03-15
AU740753B2 (en) 2001-11-15
HUP0003401A3 (en) 2003-01-28
NO995198D0 (no) 1999-10-25
CZ298429B6 (cs) 2007-10-03
HUP0100284A2 (hu) 2001-06-28
UA55448C2 (uk) 2003-04-15
NO995134D0 (no) 1999-10-21
WO1998048818A1 (en) 1998-11-05
IN187157B (enExample) 2002-02-16
TR199902631T2 (xx) 2000-01-21
EG23685A (en) 2007-05-09
PE84799A1 (es) 1999-09-16
NZ500346A (en) 2001-08-31
PL336889A1 (en) 2000-07-17
EA004881B1 (ru) 2004-08-26
NZ337828A (en) 2001-06-29
CA2288143A1 (en) 1998-11-05
BR9809304B1 (pt) 2011-02-08
CN1254284A (zh) 2000-05-24
TR199902529T2 (xx) 2000-02-21
IL132502A0 (en) 2001-03-19
WO1998048822A1 (en) 1998-11-05
CZ381099A3 (cs) 2000-03-15
PE86299A1 (es) 1999-09-17
SI0875252T1 (en) 2005-06-30
IN183798B (enExample) 2000-04-15
MY120984A (en) 2005-12-30
AR012010A1 (es) 2000-09-13
SV1998000051A (es) 1998-12-11
PL336420A1 (en) 2000-06-19
EA199900979A1 (ru) 2000-06-26
EP0875252A2 (en) 1998-11-04
JP4383546B2 (ja) 2009-12-16
IL132325A (en) 2005-07-25
ATE285788T1 (de) 2005-01-15
JP2001527543A (ja) 2001-12-25
PL195642B1 (pl) 2007-10-31
CO4940438A1 (es) 2000-07-24
AU743531B2 (en) 2002-01-31
UA73071C2 (en) 2005-06-15
NO995198L (no) 1999-10-25
HU224826B1 (en) 2006-02-28
US6436397B1 (en) 2002-08-20
NO995134L (no) 1999-12-21
HUP0100284A3 (en) 2003-08-28
CN1227025C (zh) 2005-11-16
CO4950523A1 (es) 2000-09-01
CN1261280A (zh) 2000-07-26
PL195090B1 (pl) 2007-08-31
EA199900980A1 (ru) 2000-04-24
AU740753C (en) 2002-10-10
AU7258998A (en) 1998-11-24
TWI242443B (en) 2005-11-01
SV1998000050A (es) 1999-01-13
EP0875252A3 (en) 2000-07-26
US6395270B1 (en) 2002-05-28
US6159468A (en) 2000-12-12
HUP0003401A2 (hu) 2001-02-28
HK1016472A1 (en) 1999-11-05
AU7161898A (en) 1998-11-24
BR9809292A (pt) 2000-07-04
MY118591A (en) 2004-12-31
ZA983497B (en) 1999-10-25
KR100450856B1 (ko) 2004-10-02
PT875252E (pt) 2005-03-31
AR015598A1 (es) 2001-05-16
EA002149B1 (ru) 2001-12-24
KR100564189B1 (ko) 2006-03-27
TW585871B (en) 2004-05-01
DE69828330D1 (de) 2005-02-03
IL132325A0 (en) 2001-03-19
EP0875563A3 (en) 2000-08-02
ID22933A (id) 1999-12-16
ES2234072T3 (es) 2005-06-16
US6162629A (en) 2000-12-19
CA2288143C (en) 2012-08-21
CA2287267A1 (en) 1998-11-05
CA2287267C (en) 2006-08-15
ID23172A (id) 2000-03-23
EP0875563A2 (en) 1998-11-04
KR20010020242A (ko) 2001-03-15
BR9809304A (pt) 2000-10-17

Similar Documents

Publication Publication Date Title
CN1235638C (zh) 活性蛋白c制剂
US6630137B1 (en) Activated protein C formulations
JP6425674B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
KR100491281B1 (ko) 저당함량을가지는안정한알부민무함유재조합인자Vlll의제제
FI85335B (fi) Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition.
JP2002527490A (ja) 敗血症を治療する方法
CN1326356A (zh) 治疗病毒性出血热的方法
CN105925545A (zh) 干燥转谷氨酰胺酶组合物
US20050143283A1 (en) Activated protein c formulations
CN1168492C (zh) 活化蛋白c在制药中的应用以及含有活化蛋白c的单元剂型
JP2004511428A (ja) 凝固亢進状態を処置するための製剤および方法
HK1016472B (en) Activated protein c formulations
EP1561469A1 (en) Activated Protein C Formulations
RU2257224C1 (ru) Способ получения концентрата плазмина человека и продукт для использования в медицине
CN115335074A (zh) 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
CN1303428A (zh) 人蛋白c多肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060111